A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intervenous Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Trial Profile

A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intervenous Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs Clofarabine (Primary) ; Antithymocyte globulin; Busulfan; Fludarabine; Methotrexate; Tacrolimus
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jan 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.
    • 29 Jan 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
    • 27 Jan 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top